Lowell D. Markley

Advent of Imidazo[1,2-<i>a</i>]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity

Garrett C. Moraski, Lowell D. Markley, Philip A. Hipskind et al. · ACS Medicinal Chemistry Letters · 2011 · 181 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Generation and exploration of new classes of antitubercular agents: The optimization of oxazolines, oxazoles, thiazolines, thiazoles to imidazo[1,2-a]pyridines and isomeric 5,6-fused scaffolds

Garrett C. Moraski, Lowell D. Markley, Mayland Chang et al. · Bioorganic & Medicinal Chemistry · 2012 · 115 citations

Pharmacy, Chemistry, Medicinal Chemistry +12

Advancement of Imidazo[1,2-<i>a</i>]pyridines with Improved Pharmacokinetics and nM Activity vs. <i>Mycobacterium tuberculosis</i>

Garrett C. Moraski, Lowell D. Markley, Jeffrey W. Cramer et al. · ACS Medicinal Chemistry Letters · 2013 · 112 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +15

Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates

Garrett C. Moraski, Allen G. Oliver, Lowell D. Markley et al. · Bioorganic & Medicinal Chemistry Letters · 2014 · 51 citations · Full text

Pharmacy, Chemistry, Medicinal Chemistry +14

Characterization of the Anopheles gambiae octopamine receptor and discovery of potential agonists and antagonists using a combined computational-experimental approach

Kevin Kastner, Douglas A. Shoue, Guillermina Estiú et al. · Malaria Journal · 2014 · 41 citations · Full text

Pharmacy, Entomology, Molecular Biology +17